Solriamfetol, a new treatment for ADHD, showed a 45% reduction in symptoms in a Phase 3 trial. This treatment targets dopamine and norepinephrine reuptake and offers a safer alternative for those who don’t respond well to traditional stimulants.
Solriamfetol, a new treatment for ADHD, showed a 45% reduction in symptoms in a Phase 3 trial. This treatment targets dopamine and norepinephrine reuptake and offers a safer alternative for those who don’t respond well to traditional stimulants.